Alerts will be sent to your verified email
Verify Email
KABRADG
|
Kabra Drugs
|
Medicamen Organics
|
Vineet Laboratories
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
65.41 % | 7.97 % | 6.26 % |
|
5yr average Equity Multiplier
|
-11.28 | 3.29 | 3.18 |
|
5yr Average Asset Turnover Ratio
|
0.0 | 0.76 | 1.36 |
|
5yr Avg Net Profit Margin
|
0.0 | 3.89 % | 1.11 % |
|
Price to Book
|
1.62 | 0.0 | 2.82 |
|
P/E
|
0.0 | 11.89 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
0.0 | -32.99 Days | 89.15 Days |
|
Inventory Days
|
0.0 | 70.3 Days | 66.38 Days |
|
Days Receivable
|
0.0 | 198.36 Days | 80.91 Days |
|
Days Payable
|
0.0 | 321.34 Days | 81.06 Days |
|
5yr Average Interest Coverage Ratio
|
-836.53 | 3.25 | 2.14 |
|
5yr Avg ROCE
|
64.57 % | 15.06 % | 14.46 % |
|
5yr Avg Operating Profit Margin
|
0.0 | 9.86 % | 3.72 % |
|
5 yr average Debt to Equity
|
-6.16 | 1.18 | 0.69 |
|
5yr CAGR Net Profit
|
65.28 % | 51.57 % | n/a |
|
5yr Average Return on Assets
|
-21.32 % | 2.68 % | 1.2 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
0.0 | 59.73 % | 29.26 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 0.04 % | -6.7 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Kabra Drugs
|
Medicamen Organics
|
Vineet Laboratories
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|